View in EDS

The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study.

Saved in:
Bibliographic Details
Title: The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study.
Authors: Bryant, Zachary (AUTHOR), Morley, Kirsten (AUTHOR), Kerr, Jessica A. (AUTHOR), Olsson, Craig A. (AUTHOR), Slade, Tim (AUTHOR)
Source: Addiction. Dec2025, Vol. 120 Issue 12, p2448-2464. 17p.
Subjects: Mental depression risk factors, Substance abuse, Risk assessment, Mental health, Research funding, Ecstasy (Drug), Logistic regression analysis, Anxiety, Hallucinogenic drugs, Longitudinal method, Odds ratio, Confidence intervals, Data analysis software, Regression analysis, Sensitivity & specificity (Statistics), Disease complications, Adults
Geographic Terms: Victoria
Abstract: Background and aims: MDMA (3,4‐methylenedioxymethamphetamine or "Ecstasy") is the fourth‐most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid‐30s. Design: A longitudinal, population‐based study using doubly robust inverse probability treatment weighted regression analysis, a contemporary confounder adjustment technique, to examine the relationship between MDMA use in early adulthood (age 20–29) and subsequent anxiety or depression at age 35. Setting: Victoria, Australia. Participants: Data were drawn from the Victorian Adolescent Health Cohort Study (VAHCS), which began in 1992 with a statewide representative sample of 1943 Year 9 students (aged 14–15) from 44 Victorian schools. This paper uses data collected from wave 2 to wave 10 (ages 15–35). Measurements Across waves 7–9 (ages 20–29), MDMA use was categorised as any use, persistent use (none, one wave, two or more waves) and frequent use (none, infrequent, frequent). Wave 10 (age 35) outcomes were 12‐month diagnoses of major depressive disorder and anxiety disorders assessed using the Composite International Diagnostic Interview (CIDI). Findings There was little evidence linking any pattern of MDMA use in early adulthood with depressive disorders by the mid‐30s; however, compared with non‐MDMA users, the adjusted odds of an anxiety disorder were higher in those who reported past 12‐month MDMA use [odds ratio (OR) = 1.73, 95% confidence interval (CI) = 1.12–2.68), persistent MDMA use at two or more waves (OR = 2.05, 95% CI = 1.07–3.94), as well as infrequent (OR = 2.11, 95% CI = 1.14–3.92) and frequent MDMA use (OR = 2.56, 95% CI = 1.15–5.71). Conclusions: MDMA use (3,4‐methylenedioxymethamphetamine or "Ecstasy") in early adulthood appears to be associated with increased odds of anxiety disorders but not depressive disorder by the mid‐30s. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 189104083
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bryant%2C+Zachary%22">Bryant, Zachary</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morley%2C+Kirsten%22">Morley, Kirsten</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kerr%2C+Jessica+A%2E%22">Kerr, Jessica A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Olsson%2C+Craig+A%2E%22">Olsson, Craig A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Slade%2C+Tim%22">Slade, Tim</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Addiction%22">Addiction</searchLink>. Dec2025, Vol. 120 Issue 12, p2448-2464. 17p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Mental+depression+risk+factors%22">Mental depression risk factors</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse%22">Substance abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Risk+assessment%22">Risk assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+health%22">Mental health</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Ecstasy+%28Drug%29%22">Ecstasy (Drug)</searchLink><br /><searchLink fieldCode="DE" term="%22Logistic+regression+analysis%22">Logistic regression analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Anxiety%22">Anxiety</searchLink><br /><searchLink fieldCode="DE" term="%22Hallucinogenic+drugs%22">Hallucinogenic drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Odds+ratio%22">Odds ratio</searchLink><br /><searchLink fieldCode="DE" term="%22Confidence+intervals%22">Confidence intervals</searchLink><br /><searchLink fieldCode="DE" term="%22Data+analysis+software%22">Data analysis software</searchLink><br /><searchLink fieldCode="DE" term="%22Regression+analysis%22">Regression analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Sensitivity+%26+specificity+%28Statistics%29%22">Sensitivity & specificity (Statistics)</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+complications%22">Disease complications</searchLink><br /><searchLink fieldCode="DE" term="%22Adults%22">Adults</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Victoria%22">Victoria</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and aims: MDMA (3,4‐methylenedioxymethamphetamine or "Ecstasy") is the fourth‐most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid‐30s. Design: A longitudinal, population‐based study using doubly robust inverse probability treatment weighted regression analysis, a contemporary confounder adjustment technique, to examine the relationship between MDMA use in early adulthood (age 20–29) and subsequent anxiety or depression at age 35. Setting: Victoria, Australia. Participants: Data were drawn from the Victorian Adolescent Health Cohort Study (VAHCS), which began in 1992 with a statewide representative sample of 1943 Year 9 students (aged 14–15) from 44 Victorian schools. This paper uses data collected from wave 2 to wave 10 (ages 15–35). Measurements Across waves 7–9 (ages 20–29), MDMA use was categorised as any use, persistent use (none, one wave, two or more waves) and frequent use (none, infrequent, frequent). Wave 10 (age 35) outcomes were 12‐month diagnoses of major depressive disorder and anxiety disorders assessed using the Composite International Diagnostic Interview (CIDI). Findings There was little evidence linking any pattern of MDMA use in early adulthood with depressive disorders by the mid‐30s; however, compared with non‐MDMA users, the adjusted odds of an anxiety disorder were higher in those who reported past 12‐month MDMA use [odds ratio (OR) = 1.73, 95% confidence interval (CI) = 1.12–2.68), persistent MDMA use at two or more waves (OR = 2.05, 95% CI = 1.07–3.94), as well as infrequent (OR = 2.11, 95% CI = 1.14–3.92) and frequent MDMA use (OR = 2.56, 95% CI = 1.15–5.71). Conclusions: MDMA use (3,4‐methylenedioxymethamphetamine or "Ecstasy") in early adulthood appears to be associated with increased odds of anxiety disorders but not depressive disorder by the mid‐30s. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=189104083
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.70173
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 17
        StartPage: 2448
    Subjects:
      – SubjectFull: Mental depression risk factors
        Type: general
      – SubjectFull: Substance abuse
        Type: general
      – SubjectFull: Risk assessment
        Type: general
      – SubjectFull: Mental health
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Ecstasy (Drug)
        Type: general
      – SubjectFull: Logistic regression analysis
        Type: general
      – SubjectFull: Anxiety
        Type: general
      – SubjectFull: Hallucinogenic drugs
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Odds ratio
        Type: general
      – SubjectFull: Confidence intervals
        Type: general
      – SubjectFull: Data analysis software
        Type: general
      – SubjectFull: Regression analysis
        Type: general
      – SubjectFull: Sensitivity & specificity (Statistics)
        Type: general
      – SubjectFull: Disease complications
        Type: general
      – SubjectFull: Adults
        Type: general
      – SubjectFull: Victoria
        Type: general
    Titles:
      – TitleFull: The relationship between 3,4‐methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid‐30s: Findings from the Victorian Adolescent Health Cohort Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bryant, Zachary
      – PersonEntity:
          Name:
            NameFull: Morley, Kirsten
      – PersonEntity:
          Name:
            NameFull: Kerr, Jessica A.
      – PersonEntity:
          Name:
            NameFull: Olsson, Craig A.
      – PersonEntity:
          Name:
            NameFull: Slade, Tim
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 120
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1